SAMHD1 Research Digest — 2026-07-08¶
Generated by samhd1_monitor | Model: claude-sonnet-5
Summary: 88 papers evaluated | 12 high-relevance (≥7) | 33 medium (5–6) | 43 low (3–4) | 0 scored <3
🔴 High Relevance (Score 7–10)¶
Auto-added to Zotero (threshold ≥6)
Upregulation of macrophage UPP1 promotes lung adenocarcinoma metastasis through an mtROS-cGAS-NLRP3 inflammasome axis. (from Oncology (tumor immunology/lung adenocarcinoma))
Feng MingTao; Gao Chao; Yang YueChao; Li Deheng; Zhou Changshuai — Cell death discovery 2026
Score: 7/10 | Pathways: cGAS-STING, NLRP3, mito-ROS-NF-kB, nucleotide-rewiring, treatment-target
Demonstrates a mechanistically analogous nucleotide-dysregulation → mtROS → mtDNA leakage → cGAS-STING → NLRP3 → IL-1β axis in macrophages driving tumor progression, closely paralleling the PURPLE/BLUE/GOLD SAMHD1 pathways though in an oncology (lung adenocarcinoma) rather than SAMHD1 context.
DOI: 10.1038/s41420-026-03226-4
Melatonin alleviates rheumatoid arthritis via elimination of damaged mitochondria. (from Rheumatology)
Wang Bo; Wu Yanglin; Li Gen; Che Zhenjia; Sun Qi — Autophagy 2026
Score: 7/10 | Pathways: NLRP3, mito-ROS-NF-kB, clinical-phenotype, treatment-target
Demonstrates mitophagy-mediated clearance of damaged mitochondria/mtDNA suppresses NLRP3 inflammasome activation and cytokine release in RA models, directly paralleling the family's mitochondrial-NLRP3 mechanism and RA phenotype seen in the pedigree.
DOI: 10.1080/15548627.2026.2689419
Copper Exposure Promotes Mitochondrial VDAC Oligomerization and Releases mtDNA to Induce Pyroptosis in Pig Hepatocytes. (from Veterinary toxicology/agricultural food chemistry)
Qiu Wenyue; Chen Wei; Yang Shanglong; Xi Hao; Liao Jianzhao — Journal of agricultural and food chemistry 2026
Score: 7/10 | Pathways: VDAC1, NLRP3, treatment-target
Demonstrates the exact VDAC1 oligomerization → mtDNA release → NLRP3 pyroptosis axis (Loop B/BLUE-adjacent) using the same VBIT-4/MCC950 pharmacologic tools referenced in the SAMHD1 mechanism, though in a copper toxicity/veterinary model rather than SAMHD1 context.
DOI: 10.1021/acs.jafc.6c03617
STAT2 R148 variant: A 16th-century founder mutation and clinical response to high-dose JAK inhibitor therapy. (from Clinical genetics/pediatric neuroimmunology)
Parvaneh Nima; Molatefi Rasol; Gruber Conor; Biglari Sajjad; Moradi Leila — Journal of human immunity 2026
Score: 7/10 | Pathways: JAK-STAT, AGS-spectrum, treatment-target, clinical-phenotype
STAT2 R148 causes type I interferonopathy via disrupted USP18 negative feedback, directly parallel to the IFN-I overproduction in the SAMHD1 syndrome, and demonstrates JAK inhibitor (ruxolitinib) efficacy as a therapeutic strategy relevant to this family's management.
DOI: 10.70962/jhi.20260001
Design, Synthesis, and Pharmacological Evaluation of cGAS/HDAC Dual Inhibitors for Treatment of Autoimmune Diseases. (from Medicinal chemistry/drug discovery)
Zhou Zihua; Chen Mingjie; Lei Shuyue; Wang Meng; Ding Chunyong — Journal of medicinal chemistry 2026
Score: 7/10 | Pathways: cGAS-STING, AGS-spectrum, treatment-target
A novel small-molecule dual cGAS/HDAC inhibitor with demonstrated efficacy in a murine Aicardi-Goutières syndrome model directly targets the BLUE-loop cGAS-STING pathway central to this SAMHD1 interferonopathy and offers a plausible therapeutic candidate class.
DOI: 10.1021/acs.jmedchem.6c00583
TAX1BP1 targets STING1 via microautophagy and Golgiphagy to limit inflammatory signaling. (from cell biology/autophagy)
Suklabaidya Sujit; Mohanty Suchitra; Harhaj Edward W — Autophagy 2026
Score: 7/10 | Pathways: cGAS-STING, treatment-target
Describes a novel negative-feedback mechanism (TAX1BP1-mediated Golgiphagy/microautophagy) that degrades activated STING1, directly relevant to the BLUE pathway's IFN-I amplification and a potential therapeutic node for dampening chronic interferonopathy in SAMHD1 A565T carriers.
DOI: 10.1080/15548627.2026.2658230
Hydroxycinnamic acids target COPII cargo sorting machinery to attenuate inflammation via the cGAS-STING axis. (from Ethnopharmacology/hepatology-metabolic disease)
Ma Xiaojing; Wang Jiaming; Guo Yakun; Nan Yanan; Guo Linyue — Journal of ethnopharmacology 2026
Score: 7/10 | Pathways: cGAS-STING, treatment-target, NF-kB-IKK
Demonstrates a druggable choke point (COPII/Sec24-mediated STING trafficking) directly upstream of the cGAS-STING-TBK1-IRF3 axis central to the BLUE/RED interferon loops, with therapeutic implications for metabolic/inflammatory phenotypes relevant to this family's syndrome.
DOI: 10.1016/j.jep.2026.121881
Breaking a mitochondrial danger-STING feed-forward amplifier preserves alveolar-capillary architecture and dampens interferon-chemokine signaling in acute lung injury. (from pulmonology/critical care)
Elmorsy Elsayed A; Amer Maha M; Hamad Rabab S; Abdel-Hamed Mohamed R; Farrag Als — Tissue & cell 2026
Score: 7/10 | Pathways: cGAS-STING, treatment-target, mito-ROS-NF-kB, NF-kB-IKK
Demonstrates a mitochondrial danger signal-cGAS/STING-IFN feed-forward loop driving tissue injury and its pharmacological interruption, directly paralleling the BLUE/RED loop mechanism and STING-targeted therapeutics relevant to the SAMHD1 interferonopathy model, though in an acute lung injury rather than SAMHD1 context.
DOI: 10.1016/j.tice.2026.103514
CMPK2 promotes M1 macrophage polarization in sepsis-induced acute lung injury via NLRP3/NF-κB signalling. (from Critical care/pulmonology (sepsis-induced acute lung injury))
Li Cheng; Ding Peng; Zheng Zenglu; Wei Huawei; Yang Yutong — International immunopharmacology 2026
Score: 7/10 | Pathways: NLRP3, NF-kB-IKK, mito-dNTP-transport, nucleotide-rewiring
CMPK2, a key player in the CMPK2-vs-PNC1/2 mitochondrial dNTP supply axis directly implicated in the SAMHD1 mechanism, is shown here to drive NLRP3/NF-κB-mediated macrophage inflammation and mitochondrial ultrastructural damage in sepsis, providing mechanistic support for the CMPK2-mitochondrial-inflammasome link even though SAMHD1 itself is not studied.
DOI: 10.1016/j.intimp.2026.116906
Endosymbiotic theory of aging revisited: Age-related leakage of mitochondrial dsDNA/RNA stimulates cytosolic nucleic acid sensors which remodel the immune network and promote the aging process. (from Evolutionary biology / gerontology)
Salminen Antero; Kaarniranta Kai; Kauppinen Anu — 2026
Score: 7/10 | Pathways: cGAS-STING, NLRP3, AGS-spectrum, other
This review directly supports the BLUE loop mechanism (mtDNA/dsRNA leakage activating cGAS-STING and related sensors driving IFN-I and inflammaging) central to the SAMHD1 A565T pathophysiology, though it addresses general aging rather than SAMHD1 specifically.
DOI: 10.1007/s10522-026-10470-9
Specific bile acids can elicit the type-I interferon response through the cGAS-STING pathway. (from Hepatology/bile acid metabolism)
He Jianan; Huang Ziyan; Xiong Caiwan; Huang Zhicheng; Yan Hao — 2026
Score: 7/10 | Pathways: cGAS-STING, VDAC1, treatment-target
Demonstrates bile acid-induced mtDNA release via Bax/Bak pores activating cGAS-STING/IFN-I, directly paralleling the BLUE pathway mechanism (VDAC1/mtDNA-cGAS-STING) and connecting to the family's hepatology phenotypes (cholecystectomy clustering, bile acid-innate immunity axis).
DOI: 10.1186/s12964-026-03036-2
Senataxin loss induces cGAS–STING-mediated mitochondrial dysfunction (from Neurology/neurodegeneration (ataxia-AOA2))
Fishburn Judith L.A.; Zhao Hongchang; Fosselman Will; Flores Julian; Wong Megan — preprint (preprint) 2026
Score: 7/10 | Pathways: cGAS-STING, AGS-spectrum, POLG-mtDNA, clinical-phenotype
Demonstrates cGAS-STING-driven mitochondrial dysfunction (ROS, hyperfusion, reduced function) from a distinct genomic instability trigger, directly paralleling the BLUE loop mechanism proposed for SAMHD1 haploinsufficiency and reinforcing the interferon-mitochondrial convergence model.
DOI: 10.64898/2026.06.26.734838
🟡 Medium Relevance (Score 5–6)¶
Score ≥6 auto-added to Zotero; lower scores: review manually
Targeting IMPDH to inhibit SAMHD1 in KMT2A-rearranged leukaemia. (from Oncology/hematology)
Klootsema Yolande; Tsesmetzis Nikolaos; Sharma Sushma; Hofmann Sophia; Thier Jon — Cell cycle (Georgetown, Tex.) 2026
Score: 6/10 | Pathways: dNTPase, treatment-target
This paper directly studies SAMHD1's dNTPase activity and GTP/dGTP allosteric regulation in the context of leukemia chemotherapy resistance, providing mechanistic insight into SAMHD1 dNTP pool control relevant to the core disease mechanism, though not directly tied to A565T or the interferon-mitochondrial syndrome.
DOI: 10.1080/15384101.2025.2601796
Inhibition of toll-like receptor 4 by allicin suppresses mitochondrial DNA-mediated inflammation and pyroptosis to alleviate myocardial ischemia-reperfusion injury. (from Cardiology)
Liang Shichao; Wu Song; Yin Jiajie; Gao Tong; Liu Mengru — Phytomedicine : international journal of phytotherapy and phytopharmacology 2026
Score: 6/10 | Pathways: cGAS-STING, NLRP3, NF-kB-IKK, mito-ROS-NF-kB, treatment-target
Demonstrates mtDNA leakage driving cGAS-STING and NLRP3-pyroptosis via TLR4 in cardiac ischemia-reperfusion, mechanistically parallel to the BLUE/PURPLE loops and NF-kB priming axis though in a cardiology context rather than SAMHD1-driven interferonopathy.
DOI: 10.1016/j.phymed.2026.158513
Asiatic acid mitigates PM2.5-elicited cardiomyocyte pyroptosis via suppression of mtDNA-driven cGAS-STING-NLRP3 signalling. (from Cardiology/environmental toxicology)
Chen Zefeng; Yu Xianguan; Tang Leile; Zhao Yunyue; Yang Xubin — Journal of cardiovascular pharmacology 2026
Score: 6/10 | Pathways: cGAS-STING, NLRP3, treatment-target
Demonstrates mtDNA-driven cGAS-STING-NLRP3-pyroptosis cascade in cardiomyocytes and a natural compound that blocks it, directly mirroring the Loop A/B mechanism (VDAC1-independent mtDNA release, TFAM loss, cGAS-STING-NLRP3 axis) relevant to the family's cardiac and interferonopathy phenotype though not SAMHD1-specific.
DOI: 10.1097/FJC.0000000000001858
Dendrobine alleviates lung injury in septic mice by inhibiting mitochondrial-endoplasmic reticulum crosstalk-mediated NLRP3 inflammasome activation. (from critical care/sepsis pharmacology)
Zhang Shichao; Luo Kaihang; Wei Xinyue; Qing Cheng; Zhang Jianguo — Journal of pharmacological sciences 2026
Score: 6/10 | Pathways: VDAC1, NLRP3, treatment-target
Demonstrates VDAC1-centered mitochondrial-ROS/mtDNA release driving NLRP3 activation in macrophages, mechanistically parallel to the BLUE/GOLD loops though via IP3R-GRP75-VDAC1-HK2 glycolytic axis rather than SAMHD1/dGTP.
DOI: 10.1016/j.jphs.2026.05.007
A nucleic acid regulation strategy under mechanical stress for intervertebral disc degeneration treatment. (from Orthopedics/spine surgery (intervertebral disc degeneration))
Wang Wenchao; Huo Wenxiang; Qian Dingfei; Hou Peihong; Su Cheng — Bioactive materials 2026
Score: 6/10 | Pathways: NLRP3, treatment-target, mito-ROS-NF-kB
Describes a mtDNA leakage-cfDNA-NLRP3 inflammasome axis with MCC950 (a named NLRP3 inhibitor in the syndrome's mechanism) as therapeutic, offering a mechanistic and pharmacologic parallel to Loop B/NLRP3 activation despite different disease context.
DOI: 10.1016/j.bioactmat.2026.05.027
Silibinin restricts mitochondria-associated inflammatory pathways in LPS-stimulated murine microglia BV2 through TREM2. (from Neuroinflammation/pharmacology)
Chen Wenhui; Wang Xiaoling; Liu Panwen; Kang Yu; Hayashi Toshihiko — Cellular immunology 2026
Score: 6/10 | Pathways: cGAS-STING, NLRP3, mito-ROS-NF-kB, treatment-target
This paper demonstrates a natural compound restoring mitochondrial quality control to suppress STING and NLRP3 inflammasome activation in microglia, directly relevant to the core mitochondrial-inflammatory pathways implicated in the syndrome, though not SAMHD1-specific.
DOI: 10.1016/j.cellimm.2026.105102
Cellular copper overload mediates senescence-associated secretory phenotype induction in BV2 microglia following lead and copper exposure. (from Toxicology/Neurodegeneration)
Wang Tao; Chen Chao; Li Ran; Su Li-Hong; Tian Hao-Jie — Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 2026
Score: 6/10 | Pathways: cGAS-STING, NLRP3, mito-ROS-NF-kB
Demonstrates mtDNA release triggering cGAS-STING-NLRP3 axis via ROS in microglia, mechanistically paralleling the VDAC1/cGAS-STING-NLRP3 (Loop A/B) pathways central to this disease model, though driven by heavy metal toxicity rather than SAMHD1 dysfunction.
DOI: 10.1016/j.fct.2026.116068
cGAS-STING axis: A central regulator of neural homeostasis and neuroinflammatory pathogenesis. (from Neurology)
Zhang Jiajie; Li Jiarui; Li Yanan; Liu Chunxiao; Shi Lei — Neural regeneration research 2026
Score: 6/10 | Pathways: cGAS-STING, treatment-target, AGS-spectrum
Reviews cGAS-STING/IFN-I-driven neuroinflammation and its therapeutic targeting (including ataxia-telangiectasia, an interferonopathy-adjacent condition), directly relevant to Loop A and the AuDHD/neuro-immune features of the family but not SAMHD1-specific.
DOI: 10.4103/NRR.NRR-D-25-00367
Monosodium urate crystals induce lytic macrophage death partially dependent on both pyroptosis and necroptosis. (from Rheumatology (gout/crystal arthropathy))
Geng Zhijun; Wu Di; Hou Yajing; Kang Lulu; Zhang Xiaofeng — Clinical rheumatology 2026
Score: 6/10 | Pathways: urate-NLRP3, NLRP3
This paper details MSU crystal-induced macrophage lytic death and inflammasome dynamics, directly relevant to the GOLD stream's urate-NLRP3 axis and gout pathogenesis in the mechanism model, though it does not address SAMHD1 or dNTP metabolism.
DOI: 10.1007/s10067-026-08262-0
Nrf2 promotes NLRP3 inflammasome assembly and activation by Klf9-TXNIP axis. (from Rheumatology/immunometabolism)
Zhou You; You Hui; Xia Xin-Yu; Zhang Ke; Jiang Hui — Cell death discovery 2026
Score: 6/10 | Pathways: NLRP3, urate-NLRP3, NF-kB-NLRP3-priming, treatment-target
Describes a novel Nrf2-Klf9-TXNIP mechanism for NLRP3 inflammasome assembly and validates relevance in MSU-crystal gouty arthritis, directly relevant to the GOLD stream and urate-NLRP3 axis in the mechanism map, though not SAMHD1-specific.
DOI: 10.1038/s41420-026-03219-3
SIRT5 desuccinylates PRDX3 to promote its chaperone-mediated autophagy and mitigate mitochondrial dysfunction in MSU crystal-induced inflammation. (from Rheumatology/gout biochemistry)
Deng Yaxin; Yu Kailin; Ou Lijun; Wang Ling; Cai Yuanze — International immunopharmacology 2026
Score: 6/10 | Pathways: NLRP3, urate-NLRP3, mito-ROS-NF-kB, treatment-target
This paper details MSU crystal-induced mitochondrial dysfunction driving NLRP3 activation via PRDX3 accumulation, directly relevant to the GOLD stream (dGTP-purine catabolism-uric acid-MSU-NLRP3) in the disease model, though it does not involve SAMHD1 or interferon signaling.
DOI: 10.1016/j.intimp.2026.117064
SLC16A9-mediated uric acid uptake promotes myocardial hypertrophy in dilated cardiomyopathy via NLRP3 inflammasome activation. (from Cardiology)
Hu Zhi; Ding Yiming; Wang Tingzhong; Hou Xiaolin; Song Qiang — Experimental cell research 2026
Score: 6/10 | Pathways: urate-NLRP3, NLRP3, treatment-target
Demonstrates a urate-transporter-driven NLRP3 activation axis (GOLD stream analog) in cardiomyopathy, mechanistically relevant to the uric acid/MSU-NLRP3 route implicated in the SAMHD1 syndrome and to potential cardiac phenotype in carriers.
DOI: 10.1016/j.yexcr.2026.115085
Design, semi-synthesis and biological evaluation of grandiflorenic acid derivatives as potent covalent NLRP3 inhibitors. (from medicinal chemistry/pharmacology)
Pérez-Rodríguez Daniel; Amesty Ángel; Oramas-Royo Sandra; Fernández-Vega Eva; Cu — European journal of medicinal chemistry 2026
Score: 6/10 | Pathways: NLRP3, urate-NLRP3, treatment-target
Describes novel covalent small-molecule NLRP3 inhibitors effective across multiple activation stimuli (including MSU crystals), representing a potential therapeutic strategy directly relevant to the NLRP3 hyperactivation central to the SAMHD1 A565T interferon-mitochondrial syndrome.
DOI: 10.1016/j.ejmech.2026.118935
Baricitinib in Two Pediatric Patients with COPA syndrome: A Case Series and Literature Review. (from Pediatric rheumatology/pulmonology)
Villarreal Enrique G; Dissanayake Dilan; Laxer Ronald M; Yip Kenneth W; Kritzing — Modern rheumatology case reports 2026
Score: 6/10 | Pathways: JAK-STAT, treatment-target, AGS-spectrum, clinical-phenotype
COPA syndrome is a type I interferonopathy treated with baricitinib (JAK inhibitor), directly paralleling the IFN-I/JAK-STAT treatment strategy relevant to SAMHD1-driven interferonopathy in this family.
DOI: 10.1093/mrcr/rxag052
Loss of the kinases TBK1 and IKKε sensitizes target cancer cells to T cell killing through an IFN-γ-mediated inflammatory death program. (from cancer immunology/immuno-oncology)
Sun Nicholas D; Carr Allison R; Krogman Erica N; Chawla Yogesh; Zhong Jun — Science signaling 2026
Score: 6/10 | Pathways: NF-kB-IKK, JAK-STAT, treatment-target, other
Demonstrates TBK1/IKKε (non-canonical NF-kB/IFN kinases central to the disease's NF-κB-IKK crosstalk axis) as inhibitors of RIPK1-dependent inflammatory death and NF-κB activation, revealing a mechanistic link between IFN signaling, NF-κB, and cell death that is adjacent to the interferon-mitochondrial-NF-κB circuitry implicated in the SAMHD1 syndrome, though not SAMHD1-specific.
DOI: 10.1126/scisignal.adz7366
Targeting the cGAS-STING pathway alleviates neuroinflammation and cognitive impairment induced by chronic infection of Toxoplasma gondii. (from Neurology/Infectious Disease (parasitology-neuroinflammation))
Xing Yihui; Lv Huiling; He Peixuan; Xu Yongyao; Shen Weifan — Journal of neuroinflammation 2026
Score: 6/10 | Pathways: cGAS-STING, treatment-target, clinical-phenotype
Demonstrates cGAS-STING pathway activation driving neuroinflammation, senescence/SASP, and cognitive impairment in a chronic infectious trigger model, mechanistically relevant to the IFN-I/BLUE loop and neurologic/AuDHD phenotype axis though not SAMHD1-specific.
DOI: 10.1186/s12974-026-03937-6
Tegument protein UL16 of herpes simplex virus 1 suppresses the innate immune response by downregulating MAVS abundance via mitophagy. (from virology/microbiology (HSV-1 immune evasion))
Wang Jingwen; Zhu Rongli; Yi Ping; Gan Mengyao; Long Feng — Autophagy 2026
Score: 6/10 | Pathways: cGAS-STING, ISG15-mitophagy, other
This paper shows a viral tegument protein degrading MAVS via FUNDC1-mediated mitophagy to suppress RLR/IFN-I signaling, providing mechanistic insight into virus-induced mitophagy-immune crosstalk that parallels the mitophagy-block/interferon axis relevant to SAMHD1-driven interferonopathy and post-viral ME/CFS triggers.
DOI: 10.1080/15548627.2026.2698747
GAMG alleviates silicosis inflammation and fibrosis by targeting STING. (from Pulmonology/occupational medicine (silicosis))
Zhang Jing; Xang Miaoqing; Yao Zongze; Shao Wei; Liu Zhiyu — Ecotoxicology and environmental safety 2026
Score: 6/10 | Pathways: cGAS-STING, NF-kB-IKK, treatment-target
This paper demonstrates STING/TBK1/NF-κB pathway activation via cytosolic dsDNA driving inflammation and fibrosis, directly relevant to the BLUE loop (cGAS-STING-IRF3-IFN-I) and NF-κB crosstalk mechanisms central to the SAMHD1 syndrome, and identifies a small-molecule STING inhibitor (GAMG) with therapeutic implications.
DOI: 10.1016/j.ecoenv.2026.120405
Dexamethasone activates anti-tumor immunity in multiple myeloma by dismantling the GR-PPP1CB complex to restore STING/IRF3 signaling. (from Oncology (multiple myeloma immunotherapy))
Wang Chen; Liu Lingling; Zhang Jiale; Sun Shanliang; Lv Xinyu — Journal for immunotherapy of cancer 2026
Score: 6/10 | Pathways: cGAS-STING, treatment-target, other
This paper details TBK1-IRF3/STING pathway modulation via GR-PPP1CB in multiple myeloma, directly intersecting with the core interferon-STING axis (Loop A) relevant to SAMHD1 mechanism and the family's multiple myeloma phenotype, though not SAMHD1-specific.
DOI: 10.1136/jitc-2026-015256
BRCA1 deficiency induces NFκB-dependent type-I interferon signaling in fallopian tube epithelial cells. (from Gynecologic oncology (BRCA1/fallopian tube epithelium))
Madaan Vidushi; Kollara Alexandra; Spaner David; Brown Theodore J — Neoplasia (New York, N.Y.) 2026
Score: 6/10 | Pathways: cGAS-STING, NF-kB-IKK, JAK-STAT, treatment-target
Demonstrates cGAS-STING-TBK1-IRF3 driven type-I interferon signaling (ISG15/USP18) with NF-kB permissive crosstalk in a DNA-damage/genome-instability context, mechanistically analogous to the SAMHD1-driven IFN-I/NF-kB axis and relevant to oncology surveillance in carrier families.
DOI: 10.1016/j.neo.2026.101320
ANXA2 suppresses antiviral immunity by impeding STING Golgi translocation and disrupting the TBK1/IKKε-IRF3 axis. (from Virology/molecular microbiology)
Liu Hongyang; Xue Mengdi; Feng Chunying; Yu Jimin; Ye Guangqiang — Journal of virology 2026
Score: 6/10 | Pathways: cGAS-STING, NF-kB-IKK
Details a novel negative regulator (ANXA2) of the cGAS-STING-TBK1/IKKε-IRF3 axis central to the BLUE loop IFN-I pathway implicated in SAMHD1 haploinsufficiency pathophysiology, though not disease-specific.
DOI: 10.1128/jvi.02081-25
Loss of cGAS facilitates angiogenesis in diabetic foot ulcer healing by suppressing the STING/ferroptosis pathway. (from Endocrinology/Wound Healing (Diabetic Foot Ulcer))
Li Wei; Kang Mengyang; Zhang Guofeng; Hu Huishe; Qin Hao — International immunopharmacology 2026
Score: 6/10 | Pathways: cGAS-STING, NF-kB-IKK, treatment-target
Demonstrates cGAS-STING-TBK1-IRF3-NFkB axis driving pathology (ferroptosis, angiogenesis suppression) in a metabolic/vascular disease context, offering mechanistic and therapeutic parallels relevant to the interferon-mitochondrial syndrome's core signaling loop though not SAMHD1-specific.
DOI: 10.1016/j.intimp.2026.116684
EXOC5/SEC10 attenuates antiviral IFN-I signaling by targeting STING1 for autophagic degradation. (from Virology/molecular cell biology (autophagy trafficking))
Ma Wenqing; Xu Yanan; Yu Jie; Sun Fachao; Yu Xiao — Autophagy 2026
Score: 6/10 | Pathways: cGAS-STING, treatment-target
Describes a novel negative-feedback regulator (EXOC5-TRIM56-STING1-SQSTM1 autophagic degradation axis) of the cGAS-STING/IFN-I pathway central to the BLUE loop, offering mechanistic and therapeutic insight relevant to interferon dysregulation but not SAMHD1-specific.
DOI: 10.1080/15548627.2026.2659292
Emodin alleviates radiation-induced pulmonary fibrosis by targeting cellular senescence via the mtDNA-cGAS-STING axis. (from Pulmonology/radiation oncology)
Duan Wei; Sha Yanling; Tang Xi; Liu Riu; Su Bin — 2026
Score: 6/10 | Pathways: cGAS-STING, NF-kB-IKK, mito-ROS-NF-kB, treatment-target
Demonstrates mtDNA leakage-driven cGAS-STING-NF-κB activation and mitochondrial ROS as drivers of senescence/fibrosis, directly paralleling the BLUE/RED loop mechanisms in the SAMHD1 syndrome and offering a pharmacologic (emodin) precedent for pathway-targeted intervention.
DOI: 10.1007/s10522-026-10472-7
The novel PARP-1 inhibitor BMMP-TSC bridges mitochondrial dysfunction and innate immunity via mtDNA leakage and cGAS-STING to suppress breast cancer. (from Oncology/pharmacology (PARP-inhibitor drug development))
Wang Nan; Huang Jianting; Fei Fengshu; Ma Shiyu; Fu Qianlong — 2026
Score: 6/10 | Pathways: cGAS-STING, treatment-target
Demonstrates mtDNA leakage-driven cGAS-STING activation from mitochondrial damage in a cancer context, mechanistically parallel to the BLUE loop but in an oncology/PARP-inhibitor setting rather than SAMHD1-driven interferonopathy.
DOI: 10.1016/j.cbi.2026.112247
Neutrophil extracellular traps in gout, rheumatoid arthritis, and systemic lupus erythematosus: Mechanistic heterogeneity and therapeutic implications. (from Rheumatology)
Chen Haixu; Liu Xia; Guo Changying; Song Chao; Zeng Lianlin — Tissue & cell 2026
Score: 5/10 | Pathways: NLRP3, urate-NLRP3, cGAS-STING, clinical-phenotype
Discusses ox-mtDNA-driven cGAS/STING/IFN-I and NLRP3 activation in gout/RA/SLE, mechanistically parallel to the GOLD/BLUE loops and relevant to the family's rheumatoid arthritis and gout-adjacent phenotypes, though NETosis is not directly implicated in the SAMHD1 mechanism.
DOI: 10.1016/j.tice.2026.103735
Selective induction of mitochondrial fragmentation for cancer immunotherapy via mtDNA-Targeting AIE photosensitizer. (from Oncology/photodynamic nanomedicine)
Wang Wen-Jin; Hao Ying-Xin; Wang Yu-Meng; Xin Zhuo-Yang; Zhang Man — Biomaterials 2026
Score: 5/10 | Pathways: NLRP3, VDAC1, treatment-target
Demonstrates mtDNA release via mitochondrial permeability transition triggering NLRP3-GSDMD pyroptosis, mechanistically overlapping with the disease's Loop A/B mitochondrial-inflammasome axis, but in a cancer photodynamic therapy context rather than SAMHD1 biology.
DOI: 10.1016/j.biomaterials.2026.124211
Targeting Cathepsin B with p-coumaric acid rescues WWP1-dependent proteasomal degradation of NLRP3 in hyperuricemic nephropathy. (from Nephrology/pharmacology)
Li Fengqin; Wang Yanzhe; Liu Xia; Wu Yue; Miao Naijun — Molecular medicine (Cambridge, Mass.) 2026
Score: 5/10 | Pathways: NLRP3, urate-NLRP3, treatment-target
This paper details a urate/NLRP3-driven nephropathy mechanism (GOLD stream analog) and a novel NLRP3 proteasomal degradation pathway, offering an adjacent but non-interferon mechanistic link and a potential therapeutic angle relevant to the gout/uric acid axis in the disease profile.
DOI: 10.1186/s10020-026-01544-y
Exploration of the Potential Mechanism of Clematichinenoside AR in Alleviating Hyperuricemia Based on Untargeted Metabolomics and Nrf2 Signaling Pathway. (from Pharmacology/Nephrology (traditional Chinese medicine metabolomics))
Liang Qi; Lu Heng; Dong Hongjing; Yu Jinqian; Li Tao — Rapid communications in mass spectrometry : RCM 2026
Score: 5/10 | Pathways: NLRP3, urate-NLRP3, treatment-target
This paper demonstrates the GOLD pathway (purine catabolism → uric acid → NLRP3) mechanistically via a natural compound reducing xanthine oxidase, uric acid, and NLRP3/Caspase-1 activation, relevant to the SAMHD1 syndrome's independent gout/urate-NLRP3 axis but not SAMHD1-specific.
DOI: 10.1002/rcm.70109
Lorlatinib protects dopaminergic neurons by inhibiting ALK-mediated neuroinflammation in a mouse model of Parkinson's disease. (from Neurology/Parkinson's disease pharmacology)
Kim Do-Yeon; Kim Seong-Eun; Park Jung-Eun; Leem Yea-Hyun; Park Jin-Sun — Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2026
Score: 5/10 | Pathways: cGAS-STING, NF-kB-IKK, treatment-target
Demonstrates STING-TBK1-IRF3/NF-κB neuroinflammatory axis and microglial activation in a neurodegeneration model, mechanistically overlapping with the interferon-NF-κB crosstalk relevant to the SAMHD1 syndrome's neurological/AuDHD phenotypes, though not SAMHD1-specific.
DOI: 10.1016/j.biopha.2026.119596
Pharmacological inhibition of STING-TBK1 signaling is associated with reduced PANoptosis-like features and fibrotic remodeling in keloids. (from Dermatology/plastic surgery (fibroproliferative skin disorders))
Wang Xinyue; Tian Yuan; Luo Sai; Zhu Wenwen; Zhu Yangdong — International immunopharmacology 2026
Score: 5/10 | Pathways: cGAS-STING, treatment-target, other
Demonstrates STING-TBK1-IRF3 signaling driving inflammatory programmed cell death and fibrosis in keloids, offering a tangential mechanistic parallel (STING/TBK1 activation and pharmacological inhibition) but no direct link to SAMHD1, mitochondrial dNTP dysregulation, or the family phenotype spectrum.
DOI: 10.1016/j.intimp.2026.116869
Saturated mutagenesis screen of M-MLV reverse transcriptase identifies variants enhancing prime editing efficiency (from Molecular biology/genome engineering)
Li Hui; Wang Yifan; Zhang Chenxin; Tun Thi Thi; Yu Shi — preprint (preprint) 2026
Score: 5/10 | Pathways: prime-editing, gene-therapy-delivery
This paper improves prime editing efficiency via M-MLV RT engineering, a generic gene-correction technology platform relevant to future correction of the SAMHD1 A565T missense variant but with no immune/myeloid cell-type specificity or disease-specific demonstration.
DOI: 10.64898/2026.07.06.736660
Systematic profiling of PE6 variants establishes generalizable principles for efficient and specific prime editing (from genome engineering/molecular biology)
Shin Kyuwon; Shin Ju-Young; Woo Aram; Han Dabin; Lee Beomjun — preprint (preprint) 2026
Score: 5/10 | Pathways: prime-editing, gene-therapy-delivery
This paper advances prime editing efficiency/specificity (PE6 variants, DeepPrime6), a generalizable gene-correction technology platform potentially applicable to correcting the SAMHD1 A565T missense variant but not disease-specific or immune-cell targeted.
DOI: 10.21203/rs.3.rs-10000319/v1
🟢 Low Relevance (Score 3–4)¶
Potential specialty bridges — skim titles
Targeted Treatment for Hyperuricemia: The Drug Pipeline. (from Rheumatology/geriatrics (gout pharmacotherapy))
Barry Austin; Helget Lindsay N; Mikuls Ted R — Drugs & aging 2026
Score: 4/10 | Pathways: urate-NLRP3, treatment-target
This is a clinical gout pharmacology review touching the GOLD pathway (uric acid/NLRP3) and NLRP3-targeted therapy but does not address SAMHD1, dGTP-driven purine catabolism, or interferon-mitochondrial mechanisms specifically.
DOI: 10.1007/s40266-026-01313-w
The Dual Role of Exosomes in Gout: From Inflammatory Amplifiers to Therapeutic Regulators. (from Rheumatology)
Gao Xuege; Zhang Jiawei; Kong Xiaojuan; Xue Yanli; Fan Weimin — Inflammation 2026
Score: 4/10 | Pathways: urate-NLRP3, NLRP3
Discusses MSU crystal-driven NLRP3 inflammation and exosome biomarkers in gout, touching the GOLD stream endpoint but without SAMHD1, IFN, or mitochondrial mechanistic linkage.
DOI: 10.1007/s10753-026-02551-1
Emapalumab plus conventional therapy with or without ruxolitinib for pediatric hemophagocytic lymphohistiocytosis: a single center retrospective study. (from pediatric hematology-oncology)
Liao Meiling; Xiao Li; Gu Min; Yu Jie — Immunologic research 2026
Score: 4/10 | Pathways: JAK-STAT, treatment-target
Describes ruxolitinib (JAK1/2 inhibitor) use in a hyperinflammatory cytokine syndrome (HLH), tangentially relevant to JAK-STAT/IFN pathway therapeutics but not directly tied to SAMHD1 mechanism or family phenotypes.
DOI: 10.1007/s12026-026-09801-2
Two novel kindreds with autosomal recessive STAT2 deficiency. (from Pediatric immunology/infectious disease (inborn errors of immunity))
Kienapfel Verena; Cresens Lotte; Bizien Lucy; Vasconcelos Julia; Chbihi Marwa — Journal of human immunity 2026
Score: 4/10 | Pathways: JAK-STAT, treatment-target
STAT2 deficiency is a downstream node of the same type I IFN/JAK-STAT axis relevant to the interferonopathy mechanism and uses ruxolitinib as in the family's proposed treatment context, but is a distinct autosomal recessive disease unrelated to SAMHD1 haploinsufficiency.
DOI: 10.70962/jhi.20260037
The role of NLRP3 inflammasome in opioid-induced neurochemical markers, therapeutic effects, and adverse effects in male mice. (from Neuropharmacology/addiction medicine)
Rodriguez Myosotys; Veeragoni Dileepkumar; Carbajal Candy; Owens Florida; Eans S — Brain, behavior, and immunity 2026
Score: 4/10 | Pathways: NLRP3, NF-kB-NLRP3-priming, treatment-target
This paper demonstrates NLRP3/NF-kB/MAPK-driven neuroinflammation and MCC950 efficacy in an opioid model, offering mechanistic and pharmacological parallels (MCC950 as NLRP3 inhibitor) but no direct SAMHD1, interferon, or mitochondrial dNTP connection.
DOI: 10.1016/j.bbi.2026.106528
Persistence of large mtDNA rearrangements linked to premature aging in Pol γ exonuclease-deficient mice. (from Mitochondrial genetics/aging biology)
Wu Shilan; Lujan Scott A; Burkholder Adam B; Nissanka Nadee; Longley Matthew J — Nucleic acids research 2026
Score: 4/10 | Pathways: POLG-mtDNA, other
Demonstrates POLG exonuclease-deficiency driving large mtDNA deletions/rearrangements and premature aging, mechanistically adjacent to the PURPLE pathway's POLG-stalling/ox-mtDNA node but without any SAMHD1, dNTP pool, or immune signaling connection.
DOI: 10.1093/nar/gkag648
Precision gene editing: From proof-of-concept to curative therapies. (from Gene therapy/genetic medicine)
Cui Tongtong; Li Bojin; Cai Bingyu; Wang Hui; Li Wei — Trends in molecular medicine 2026
Score: 4/10 | Pathways: prime-editing, gene-therapy-delivery
General review of precision gene editing technologies and clinical translation with no specific mention of SAMHD1 or immune/myeloid cell targeting relevant to correcting a het missense variant like A565T.
DOI: 10.1016/j.molmed.2026.06.004
Prime editing-mediated microhomology enables efficient replacement of large DNA. (from Genome engineering / synthetic biology)
Xie Yuyang; Li Pan; He Zhiyong; Huang Honglin; Wu Dingzhou — Nucleic acids research 2026
Score: 4/10 | Pathways: prime-editing, gene-therapy-delivery
This describes a general-purpose prime editing method for large DNA replacement without disease-specific or immune/myeloid cell application, offering only generic future relevance to correcting the SAMHD1 A565T variant.
DOI: 10.1093/nar/gkag626
Emerging frontiers in genome editing: From CRISPR to next-generation technologies. (from Molecular biology/biotechnology (genome engineering))
Mishra Saurabh; Rehan Samrah; Barekzai Ahmad Mujtaba; Sharma Ambika; Raghav Alok — Methods (San Diego, Calif.) 2026
Score: 4/10 | Pathways: prime-editing, gene-therapy-delivery
A general review of genome editing technologies (CRISPR, base/prime editing, delivery systems) with only broad, non-specific relevance to future SAMHD1 A565T correction strategies rather than direct mechanistic or clinical data.
DOI: 10.1016/j.ymeth.2026.05.011
Enhanced γ-globin reactivation and sickle cell correction through a repressor-to-activator motif switch in the HBG1/2 promoters. (from Hematology/gene therapy)
Chalumeau Anne; Antoniou Panagiotis; Bou Dames Maria; Martinucci Pierre; Retana * — Molecular therapy. Nucleic acids 2026
Score: 4/10* | Pathways: gene-therapy-delivery, prime-editing
Demonstrates prime-editing and CRISPR-HDR correction in HSPCs for sickle cell disease, offering methodological relevance to future SAMHD1 missense correction strategies but no direct SAMHD1/interferon-mitochondrial pathway connection.
DOI: 10.1016/j.omtn.2026.102974
Enhancing prime editing by fusing polymerase substrate-binding proteins to reverse transcriptase. (from molecular genome engineering / biochemistry)
Zhao Dongdong; Wang Ting; Zhang Lu; Sha Taixin; Zhao Xiumei — Nucleic acids research 2026
Score: 4/10 | Pathways: prime-editing, gene-therapy-delivery
This paper describes a general prime editing efficiency improvement (PSBP fusion to RT) without any immune/myeloid cell targeting or SAMHD1-relevant application, making it only tangentially relevant as a generic gene-correction technology platform.
DOI: 10.1093/nar/gkag657
Naja atra SVPLA<sub>2</sub> upregulates hexokinase 2-driven macrophage M1 polarization via the cGAS-STING signaling activation. (from Toxicology/venom pharmacology)
Liu Jiahao; Wen Zejing; Tang Sunkun; Wu Jiajia; Han Xinyi — 2026
Score: 4/10 | Pathways: cGAS-STING, other
Demonstrates mtDNA release triggering cGAS-STING pathway activation in macrophages, mechanistically parallel to the BLUE loop but in an unrelated snake venom toxicology context with no SAMHD1 or NLRP3/interferonopathy linkage.
DOI: 10.1016/j.toxicon.2026.109208
The NF-κB-driven inflammatory cascade in ischemic stroke: Linking DAMPs, inflammasomes, and neurovascular dysfunction. (from Neurology/stroke)
Liu Yuan; Zhang Yun — Gene 2026
Score: 3/10 | Pathways: NLRP3, NF-kB-IKK, cGAS-STING
This is a general ischemic stroke NF-κB/inflammasome review with overlapping pathway components (STING, NLRP3, mtDNA DAMPs) but no connection to SAMHD1, dNTP metabolism, or the family phenotype spectrum.
DOI: 10.1016/j.gene.2026.150163
CGRP-uric acid axis in migraine: A redox-inflammatory framework linking neurovascular signaling and metabolic regulation. (from Neurology (headache/migraine medicine))
Lu Chien-Lin; Cheng Yu-Chen; Lu Kuo-Cheng — Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2026
Score: 3/10 | Pathways: urate-NLRP3, other
This migraine-focused review discusses uric acid/NLRP3/ROS/NF-kB convergence in a neurovascular context, touching the GOLD pathway (urate-NLRP3) but with no SAMHD1, interferon, or mitochondrial dNTP relevance and no clear link to the family phenotype spectrum.
DOI: 10.1016/j.biopha.2026.119709
Exploring the anti-gout mechanism of Erding granules based on network pharmacology and experimental verification. (from traditional Chinese medicine/pharmacology)
Wang Guanglei; He Liang; Zhang Yihua; Tao Xikai — Pakistan journal of pharmaceutical sciences 2026
Score: 3/10 | Pathways: urate-NLRP3
Paper links MSU-induced NLRP3/IL-1β/IL-18 release to a herbal formula via INSR/PRKCA/IGF1R signaling, touching the GOLD pathway (uric acid-NLRP3) but with no SAMHD1, interferon, or mitochondrial dNTP connection.
DOI: 10.36721/PJPS.2026.39.8.232.1
Interpretable machine learning model using peripheral blood for non-invasive detection of moderate-to-severe myelofibrosis in JAK2 V617F-positive MPNs: A multicentre pilot proof-of-concept study. (from Hematology/Oncology (myeloproliferative neoplasms))
Hao Zhuanghui; Song Miaoke; Wang Huichao; Yan Congrui; Cao Shuhua — British journal of haematology 2026
Score: 3/10 | Pathways: NLRP3, treatment-target
IL-1β/NLRP3 involvement in JAK2-mutant myelofibrosis and ruxolitinib response is tangentially related to the interferon-inflammasome axis but concerns a distinct disease (MPN) and gene (JAK2) unrelated to SAMHD1 haploinsufficiency.
DOI: 10.1111/bjh.70552
CD28+ CD8+ Tem cells with a STAT1-dependent glucocorticoid receptor deficit contribute to steroid-refractory acute GVHD. (from Transplant hematology/immunology)
Pan Zengkai; Deng Yujun; Huang Jingtao; Bian Haoxing; Chen Yiyin — Blood 2026
Score: 3/10 | Pathways: JAK-STAT, treatment-target
This paper describes STAT1-GR crosstalk and JAK inhibition in steroid-refractory GVHD, a peripheral JAK-STAT/inflammation mechanism sharing pathway components (STAT1, ruxolitinib) but with no direct link to SAMHD1, cGAS-STING, NLRP3, or mitochondrial dNTP biology.
DOI: 10.1182/blood.2025032587
Metagenomic profiling of gut microbiome in post-cholecystectomy patients with diarrhea: a nested case-control study. (from Gastroenterology/microbiome research)
Ye Jiayi; Mao Peiyu; Li Bo; Hao Ying; Chen Yuwen — BMC microbiology 2026
Score: 3/10 | Pathways: clinical-phenotype
Cholecystectomy clustering is a tracked family phenotype but this paper's gut microbiome/diarrhea findings have no direct mechanistic link to SAMHD1, interferon, or inflammasome pathways.
DOI: 10.1186/s12866-026-05346-4
Maternal gut microbiota mediates prenatal stress-induced fetal blood‒brain barrier dysfunction. (from Obstetrics/neurodevelopmental microbiome research)
Wang Xuanping; Zhou Fang-Yue; Wu Ting; Duan Chenchi; Luo Xukai — Gut microbes 2026
Score: 3/10 | Pathways: pregnancy-fetal, JAK-STAT, other
This paper involves IFN-β signaling and maternal-fetal axis relevant tangentially to interferonopathy biology but lacks any SAMHD1, cGAS-STING, NLRP3, or mitochondrial dNTP mechanism connection.
DOI: 10.1080/19490976.2026.2631242
Targeting the ATX-LPA Axis Overcomes TKI Resistance and Immunosuppression in Renal Cell Carcinoma via Dual Inhibition of AKT/mTOR and TBK1/IRF3 Pathways. (from Oncology (renal cell carcinoma/tumor immunology))
Luo Jinchen; Lin Hansen; Feng Haoqian; Tan Lei; Liu Xi — Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2026
Score: 3/10 | Pathways: treatment-target, other
This paper concerns TBK1/IRF3-mediated PD-L1 upregulation in renal cell carcinoma via the ATX-LPA axis, touching the TBK1/IRF3 node shared with the interferonopathy mechanism but in an oncology/immune-evasion context unrelated to SAMHD1 dNTPase biology or mitochondrial dysfunction.
DOI: 10.1002/advs.76352
A novel role of circCPSF6 regulating antiviral innate immunity via miR-665 and PCBP2-IPS-1 axis in IAV infection. (from Virology/RNA biology)
Meher Aparna; Chaudhary Riya; Kumar Himanshu — Molecular therapy. Nucleic acids 2026
Score: 3/10 | Pathways: JAK-STAT, other
This paper describes circRNA-mediated regulation of antiviral IFN signaling (MyD88/STAT2/IKKε/IPS-1) in influenza infection, tangentially touching IFN-I pathway machinery but with no direct SAMHD1, mitochondrial, NLRP3, or inflammasome connection.
DOI: 10.1016/j.omtn.2026.102973
[Effect of electroacupuncture on acute gastric mucosal injury in mice by regulating macrophage polarization mediated by the cGAS-STING signaling pathway]. (from Traditional Chinese medicine / acupuncture research in gastroenterology)
Xu Yuan-Bo; Wang Jing-Ji; Gao Qiu-Jin; Xu Xin-Yue; He Ruo-Nan — Zhen ci yan jiu = Acupuncture research 2026
Score: 3/10 | Pathways: cGAS-STING, other
Uses cGAS-STING signaling terminology but in an unrelated context (electroacupuncture treatment of ethanol-induced gastric mucosal injury and macrophage polarization), with no connection to SAMHD1, mitochondrial dNTP dysregulation, or the interferon-mitochondrial syndrome described.
DOI: 10.13702/j.1000-0607.20251161
Immune cell-intrinsic STING activation drives tumor ferroptosis via AA-mediated suppression of ACSL4 lactylation in colorectal cancer. (from Oncology (colorectal cancer immunometabolism))
Ding Lina; Du Wenqi; Zhu Jing; Zhang Yuxiang; Wang Xingyue — Proceedings of the National Academy of Sciences of the United States of America 2026
Score: 3/10 | Pathways: cGAS-STING, other
This paper uses STING signaling in an oncology/ferroptosis context unrelated to SAMHD1, mitochondrial dNTP dysregulation, or interferonopathy syndrome mechanisms, though it touches the STING node relevant to the broader pathway architecture.
DOI: 10.1073/pnas.2524594123
Smart-responsive lentinan-DMXAA conjugate for synergistic STING-mediated pancreatic cancer immunotherapy. (from Oncology/pharmaceutical nanomedicine)
Zhang Zhengxian; Zhu Xin; Cui Jingru; Han Jiale; Wang Jiaxing — International journal of pharmaceutics 2026
Score: 3/10 | Pathways: cGAS-STING, treatment-target
This is a drug-delivery oncology paper exploiting STING agonism (TBK1-IRF3-IFN-beta) for pancreatic cancer immunotherapy, sharing the STING pathway node but with no SAMHD1, mitochondrial, or NLRP3 connection to the syndrome mechanism.
DOI: 10.1016/j.ijpharm.2026.126996
Cellular hnRNP D promotes influenza A virus replication by inhibiting TBK1-IRF3-mediated innate immune response. (from virology/molecular virology)
Xu Chenchen; Peng Yunling; Liu Shuhui; Xie Ran; Feng Duanchenxi — Journal of virology 2026
Score: 3/10 | Pathways: cGAS-STING, other
This paper describes TBK1-IRF3 antagonism by an influenza viral evasion protein, touching the cGAS-STING/IFN-I axis but with no connection to SAMHD1, mitochondrial dNTP pools, or NLRP3 pathways central to this disease.
DOI: 10.1128/jvi.00257-26
Breaking the oncogene-immune suppression cycle through dual HER2 silencing and innate immune activation by biomineralized DNA nanocomplexes. (from Oncology/nanomedicine drug delivery)
Duan Yubei; Huang Jiaxin; Huang Tianping; Yang Kaige; Qi Liwen — Journal of controlled release : official journal of the Controlled Release Society 2026
Score: 3/10 | Pathways: cGAS-STING
Involves cGAS-STING pathway activation but in a cancer nanomedicine context unrelated to SAMHD1 dNTPase biology, mitochondrial dysfunction, or the family phenotype spectrum.
DOI: 10.1016/j.jconrel.2026.115009
The TRIM27/STING Axis Mediates Schisandrin B-Induced Inhibition of Myeloid-Derived Suppressor Cells Accumulation to Potentiate Anti-PD-1 Immunotherapy in Hepatocellular Carcinoma. (from Oncology/immunotherapy)
Huang Lei; Li Siying; Li Ziqing; Qin Zhuo; Sun Yanan — Phytotherapy research : PTR 2026
Score: 3/10 | Pathways: cGAS-STING, other
Involves STING pathway regulation via TRIM27 in cancer immunotherapy context, but focuses on tumor microenvironment/MDSCs in HCC rather than SAMHD1-driven interferonopathy or mitochondrial dysfunction mechanisms.
DOI: 10.1002/ptr.70368
Scoparone inhibits the progression of gastric cancer by regulating the PIN1/STING/TBK1/IRF3 signaling pathway. (from Oncology/pharmacology)
Zhao Na; Wang Ping — Toxicology and applied pharmacology 2026
Score: 3/10 | Pathways: cGAS-STING
Involves STING/TBK1/IRF3 signaling but in the context of gastric cancer drug mechanism unrelated to SAMHD1 or interferonopathy pathophysiology, with STING activation here being tumor-suppressive rather than pathogenic.
DOI: 10.1016/j.taap.2026.117838
Transglutaminase 2 regulates innate immunity: mechanisms and therapeutic implications. (from biochemistry/enzymology (transglutaminase))
D'Eletto Manuela; Occhigrossi Luca; Colasuonno Fiorella; Bellanca Veronica; Di S — Oncoimmunology 2026
Score: 3/10 | Pathways: cGAS-STING, other
TG2 modulation of TBK1/type I interferon signaling touches tangentially on the IFN-I axis but has no direct connection to SAMHD1, dNTPase, NLRP3, or mitochondrial mechanisms central to this disease profile.
DOI: 10.1080/2162402X.2026.2665505
Viral Infections and Neurodegenerative Diseases: Reinterpreting the Crosstalk Through a Dual-Role Lens. (from neurology/virology gene therapy engineering)
Tahmtan Alireza; Nissapatorn Veeranoot; Saravanabhavan Shanmuga Sundar; Taherkha — Current microbiology 2026
Score: 3/10 | Pathways: gene-therapy-delivery, other
Reviews viral contributions to neurodegeneration and viral vector gene therapy technology broadly, with only tangential overlap to SAMHD1 interferonopathy mechanisms (mitochondrial dysfunction, neuroinflammation) and general gene-editing delivery methods rather than myeloid-targeted correction.
DOI: 10.1007/s00284-026-05018-6
Nanomaterials for subcellular organelle targeting: unlocking new avenues for enhanced therapeutic effectiveness. (from Nanomedicine/drug delivery)
Solouki Kiarash; Sohail Muhammad — Journal of drug targeting 2026
Score: 3/10 | Pathways: gene-therapy-delivery, other
General nanomaterial organelle-targeting review with brief mention of CRISPR/base/prime editing delivery, but no disease-specific mechanistic link to SAMHD1 pathways.
DOI: 10.1080/1061186X.2026.2691784
Re-balancing immunity with CRISPR-Cas9: Novel strategies for cancer and autoimmune disorders. (from genome editing/biotechnology)
Ren Xuanqi; Zhou Ziyang; Kong Lingkai; Guo Yibo; Liu Yan — Biotechnology advances 2026
Score: 3/10 | Pathways: prime-editing, gene-therapy-delivery, other
General review of CRISPR-Cas9 strategies (KO/KI/CRISPRa/CRISPRi/base/prime editing) for cancer and autoimmunity is only tangentially relevant as background on gene-editing tools without any SAMHD1, interferon, or mitochondrial pathway content.
DOI: 10.1016/j.biotechadv.2026.108921
Strategies and Advances in Site-Specific Integration of Exogenous Large Genes. (from Genome engineering/gene therapy methodology)
Wu Zhencheng; Chen Jia; Huang Manqi; Hu Wenqi; Liu Yiyu — Human gene therapy 2026
Score: 3/10 | Pathways: gene-therapy-delivery, prime-editing
This is a general review of large-fragment genomic integration technologies (HDR, prime editing/recombinases, CRISPR transposition) with no specific application to SAMHD1 correction or immune/myeloid cell delivery context relevant to this family's disease.
DOI: 10.1177/10430342261445050
Prime-edited isogenic hiPSC-derived cardiomyocyte model of short QT syndrome type 3 reveals electrophysiological phenotypes and differential drug responses. (from Cardiology/gene-editing methodology)
Kim Min Woo; Park Jeong Hwan; Lee Myeonghee; Lee Seul-Gi; Oh Jeong-Seop — Life sciences 2026
Score: 3/10 | Pathways: prime-editing
This paper demonstrates PE7 prime editing to create an isogenic iPSC-cardiomyocyte channelopathy model, relevant only as a generic gene-editing methodology reference and not to SAMHD1 or immune-mitochondrial pathways.
DOI: 10.1016/j.lfs.2026.124573
Gene Correction Enhances Dopaminergic Cell Therapy in a Nonhuman Primate Model of Parkinson's Disease. (from Neurology/regenerative medicine (gene editing methodology transferable to future SAMHD1 correction strategies))
Yan Qing; Xu Chongchong; Gao Jiangmei; Wang Pu; Wu Qingling — Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2026
Score: 3/10 | Pathways: prime-editing
Uses prime editing to correct LRRK2 mutations in iPSC-derived dopaminergic cells for Parkinson's disease, demonstrating gene correction feasibility but unrelated to SAMHD1 mechanism or interferon-mitochondrial pathways.
DOI: 10.1002/advs.76394
Generation and characterization of four iPSC and isogenic gene-corrected lines from Legius syndrome patients. (from stem cell/genetic disease modeling)
der Auweraer Seppe Van; Roth Moritz B; Vlahos Katerina; Howden Sara E; Lockhart * — Stem cell research 2026
Score: 3/10* | Pathways: prime-editing
This paper describes iPSC modeling and CRISPR/prime editing correction of SPRED1 variants in Legius syndrome, unrelated to SAMHD1 or the described interferon-mitochondrial pathways, though it demonstrates prime editing correction methodology potentially analogous to future SAMHD1 variant correction.
DOI: 10.1016/j.scr.2026.104026
Generation of gene-corrected human isogenic iPSC lines from hypertrophic cardiomyopathy patients harboring PRKAG2 mutation (c.2084A>G, p.His530Arg) using prime editing. (from Cardiology / stem cell gene editing)
Lu Zijun; Qiu Zhichao; Zhang Yao; Yang Hao; Yang Yuan — Stem cell research 2026
Score: 3/10 | Pathways: prime-editing
Uses prime editing to correct a heterozygous missense mutation causing a distinct cardiomyopathy (PRKAG2), offering only generic technical analogy to potential SAMHD1 A565T correction strategies rather than direct disease relevance.
DOI: 10.1016/j.scr.2026.104008
New Gene Therapy Strategy for β-Thalassemia. (from Hematology/gene therapy)
Liang Dongguo; Schmidt-Wolf Ingo G H; Pu Jingjing — Stem cell reviews and reports 2026
Score: 3/10 | Pathways: gene-therapy-delivery
Reviews base/prime editing for β-thalassemia gene correction, which is a technology platform of theoretical relevance to future SAMHD1 correction strategies but has no direct mechanistic or clinical overlap with the SAMHD1 interferon-mitochondrial syndrome.
DOI: 10.1007/s12015-026-11132-6
A versatile VLP-mediated CRISPR-RNP platform for precise genome editing and durable epigenome silencing in cancer. (from Oncology/gene therapy delivery engineering)
Ju Sungjin; Lee Jang Hyeon; Yang Jiyun; Jeong Tae Yeong; Choi Chang Geun — Molecular therapy. Nucleic acids 2026
Score: 3/10 | Pathways: gene-therapy-delivery
This paper describes a VLP-CRISPR-RNP delivery platform for cancer genome/epigenome editing, relevant only tangentially as a generic delivery technology rather than targeting SAMHD1 correction or immune/myeloid cells specifically.
DOI: 10.1016/j.omtn.2026.102978
Protein Nanocages as Versatile Vectors for Nucleic Acid Delivery: Main Systems and Their Loading Mechanisms. (from nanobiotechnology/bioengineering)
Coffeen Carlos Francisco; Hernández-Gutiérrez Aquetzali Estefanía; Bustos-Jaimes — Molecular biotechnology 2026
Score: 3/10 | Pathways: gene-therapy-delivery
General review of protein nanocage delivery platforms for nucleic acids without specific application to myeloid/immune cells or SAMHD1 correction, only tangentially relevant to future gene therapy translation.
DOI: 10.1007/s12033-026-01564-3
In Utero Gene Therapy for Sickle Cell Disease: Current Evidence, Ethical Considerations, and Future Directions-A Scoping Review. (from Hematology/gene therapy)
Cudjoe Efe; Thorsen Margaret; Molokwu Nneka; Russo Melissa — Clinical therapeutics 2026
Score: 3/10 | Pathways: gene-therapy-delivery, pregnancy-fetal
Discusses in utero gene editing/LNP delivery technology relevant to future SAMHD1 correction strategies but focuses on an unrelated monogenic disease (SCD) with no interferonopathy or mitochondrial mechanism overlap.
DOI: 10.1016/j.clinthera.2026.04.026
Optimizing twin prime editing components for scalable genome editing and therapy in spinocerebellar ataxia type 3. (from Neurology/genetic engineering (gene therapy technology development))
Gwon Lee Wha; Seong Jung Bae; Yeo Hyeon-Gu; Oh Yeounsun; Park Junghyung — Molecular therapy. Nucleic acids 2026
Score: 3/10 | Pathways: prime-editing, gene-therapy-delivery
This paper describes twin prime editing optimization for polyQ deletion in SCA3, a general gene-editing technology advance not targeted to SAMHD1, myeloid cells, or immune correction relevant to the disease profile.
DOI: 10.1016/j.omtn.2026.102988
CRISPR-Cas9 Therapeutics in Diabetes Mellitus: From Molecular Mechanisms and Pharmacology to Clinical Development and Translational Barriers (from Endocrinology/diabetes gene therapy)
Kumar Sachin; Singh Harshit; Sharan Lokesh; Jawa Hemangi; Chaturvedi Saurabh — preprint (preprint) 2026
Score: 3/10 | Pathways: prime-editing, gene-therapy-delivery
This paper discusses CRISPR/base/prime editing therapeutics for diabetes with no direct link to SAMHD1 mechanisms, interferonopathy, or the family's mitochondrial-inflammatory phenotype, though it touches generically on gene editing delivery platforms relevant to future SAMHD1 correction strategies.
DOI: 10.22541/authorea.15004994/v1
Pathway Coverage This Week¶
treatment-target: 43 paperscGAS-STING: 36 papersNLRP3: 24 papersother: 19 papersgene-therapy-delivery: 17 papersprime-editing: 15 papersNF-kB-IKK: 12 papersurate-NLRP3: 12 papersmito-ROS-NF-kB: 9 papersJAK-STAT: 9 papersclinical-phenotype: 7 papersAGS-spectrum: 6 papersVDAC1: 4 papersnucleotide-rewiring: 2 papersPOLG-mtDNA: 2 papersNF-kB-NLRP3-priming: 2 paperspregnancy-fetal: 2 papersmito-dNTP-transport: 1 papersdNTPase: 1 papersISG15-mitophagy: 1 papers